EpiAxis nominates EP-1302.0 as lead candidate for IND advancement, renamed epiresatide

On June 22, 2023 EpiAxis Therapeutics reported the nomination of epiresatide as its lead candidate for IND advancement (Press release, EpiAxis Therapeutics, JUN 22, 2023, View Source;utm_medium=rss&utm_campaign=epiaxis-nominates-ep-132-0-as-lead-candidate-for-ind-advancement [SID1234633038]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Epiresatide is a generation 2.1 stapled peptide specifically targeting nuclear LSD1, which offers a novel mode of action.

Designed to address the challenge of treatment resistance and prevention of cancer recurrence in numerous haematological and solid tumours, epiresatide has demonstrated superior biological performance in modulating LSD1 demethylase activities, coupled with an excellent pre-clinical safety and tolerability profile.

EpiAxis CEO Dr Jeremy Chrisp said the company is planning to move forward with the clinical development of its lead candidate, epiresatide, marking a significant milestone in its progress,

"This is a pivotal valuation inflection point for shareholders and provides momentum for EpiAxis’ fundraising and partnering activities," Dr Chrisp said.

"Currently, EpiAxis is actively seeking collaborations and investment opportunities to accelerate the development and commercialisation of epiresatide, cementing its position at the forefront of the biotechnology industry."

EpiAxis remains dedicated to transforming the lives of cancer patients and meeting the urgent need for more effective treatments. Future updates will be provided on the progress of epiresatide as the company progresses this ground-breaking therapeutic.